Botox and Botox Cosmetic

Botox is the flagship botulinum toxin type A brand associated with Allergan and now AbbVie / Allergan. Its nonproprietary name is onabotulinumtoxinA. Because Botox is the public reference point for much of the category, it is especially important to separate the brand from the broader toxin family.

In the United States, Botox is the therapeutic brand and Botox Cosmetic is the aesthetic brand. Both contain onabotulinumtoxinA, but their approved uses are defined by separate prescribing information: the Botox therapeutic label 🔗 and Botox Cosmetic label 🔗.

Botox belongs to the botulinum toxin type A group, but its units, indications, preparation, and safety language are product-specific. Botox should not be treated as a default conversion standard for Dysport, Xeomin, Jeuveau, Daxxify, Letybo, Myobloc, or any other toxin product.

Who Manufactures Botox?

Allergan Pharmaceuticals Ireland, an AbbVie company, manufactures Botox, and AbbVie Inc. distributes it in the United States, according to the current AbbVie Botox prescribing information 🔗. Allergan developed the Botox franchise before AbbVie acquired Allergan in 2020, so AbbVie is the current parent company while Allergan remains central to the product’s manufacturing, brand heritage, and aesthetics-business identity.

Product Identity

Field	Reference point
Brand	Botox / Botox Cosmetic
Nonproprietary name	OnabotulinumtoxinA
Toxin type	Botulinum toxin type A
Manufacturer	Allergan Pharmaceuticals Ireland, an AbbVie company
U.S. distributor	AbbVie Inc.
Brand heritage and current business	Allergan heritage; Allergan Aesthetics, an AbbVie company

Label Context

Botox has separate therapeutic and aesthetic label contexts in the United States. Botox and Botox Cosmetic share the onabotulinumtoxinA product identity, but the meaning of a claim depends on the specific label, indication, dose language, and patient population being discussed.

The therapeutic label gives Botox a broad medical footprint. The Botox Cosmetic label gives the brand its major aesthetic-market visibility. Neither label makes Botox a generic synonym for botulinum toxin treatment.

Botox Therapeutic

The U.S. therapeutic label covers bladder disorders, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, blepharospasm, and strabismus. Eligibility differs by indication: some uses specify adults, while certain indications include pediatric patients. Prior-treatment requirements also apply to the bladder and axillary hyperhidrosis indications. These boundaries are defined in the Botox prescribing information 🔗.

Botox Cosmetic

The U.S. aesthetic label covers temporary improvement of moderate to severe glabellar lines, lateral canthal lines / crow’s feet, forehead lines, and platysma bands in adults, associated with the muscles specified in the Botox Cosmetic prescribing information 🔗. The shared ingredient does not extend this label to every cosmetic use of botulinum toxin.

FDA approved Botox Cosmetic for glabellar lines on April 12, 2002 (FDA approval letter 🔗). Later indication expansions appear in the U.S. FDA approval timeline, while the U.S. indication matrix separates the therapeutic and aesthetic labels and their patient limits.

Market Interpretation

Botox is a category reference brand because it connects early regulatory history, broad clinical recognition, and strong consumer awareness. That visibility can make cross-brand discussion easier for readers, but it can also blur important distinctions.

Comparisons with Dysport, Xeomin, Jeuveau, Daxxify, or Letybo should be framed around product identity, label context, evidence, and local regulation. A headline unit number, patient anecdote, or brand familiarity cannot establish equivalence.

Graph Connections

AbbVie / Allergan supplies the company context behind Botox. Justinus Kerner and Émile van Ermengem anchor the pre-product botulism and microbiology history, Edward J. Schantz anchors the toxin-science and purification background, Alan B. Scott anchors the therapeutic Oculinum / Botox origin story, and Richard Clark, Jean Carruthers, and Alastair Carruthers anchor the early aesthetic and Botox Cosmetic glabellar-line adoption pathway.

Joseph Jankovic, M.D. connects early controlled dystonia trials with the wider neurological adoption of therapeutic botulinum toxin. Mitchell Brin, M.D. connects clinical botulinum toxin research with later Allergan and AbbVie development, licensure, and neurotoxin-franchise science. David E. I. Pyott explains the Allergan executive period in which Botox Cosmetic gained its U.S. glabellar-line approval and the Botox franchise became a major global commercial reference point.

Botulinum toxin explains the broader medicine family, while type A vs type B separates Botox from type B products such as Myobloc / Neurobloc.